Shionogi enrols first patients in Esprit trial for Pompe disease

​Shionogi has enrolled the first patients in its global Phase II clinical trial, Esprit, assessing the investigational drug S-606001 in adults with LOPD.

The post Shionogi enrols first patients in Esprit trial for Pompe disease appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.